Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 171

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 171
---
able upon issuance. We are also registering the shares of our Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants, May 2025 Warrants and Placement Agent Warrants offered hereby.

Common Stock

The description of our Common Stock under the section “Description of Our Securities—Common Stock” in this prospectus is incorporated herein by reference.

May 2025Warrants

The following summary of certain terms and provisions of the May 2025 Warrants included with the shares of Common Stock and the Pre-Funded Warrants that are being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrant Agent Agreement between us and VStock Transfer, LLC, as Warrant Agent, and the form of the May 2025 Warrants, both of which will be filed as exhibits to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the Warrant Agent Agreement, including the annexes thereto, and the form of May 2025 Warrant for a complete description of the terms and conditions of the May 2025 Warrants.

Warrant Stockholder Approval

The May 2025 Warrants are exercisable after issuance.

We have agreed to hold a stockholders’ meeting no later than 90 days from the closing date of this offering in order to seek Warrant Stockholder Approval. If we do not obtain Warrant Stockholder Approval at the first meeting, the Company shall call a meeting every three (3) months thereafter to seek Stockholder Approval until the earlier of the date Stockholder Approval is obtained or the May 2025 Warrants are no longer outstanding. We cannot assure you that we will be able to hold the meeting in this timeframe or obtain Stockholder Approval. In the event that we are unable to obtain the Warrant Stockholder Approval, the Anti-Dilution Adjustment will not be permitted. “Warrant Stockholder Approval” means approval from the stockholders of the Company: (a) of Anti-Dilution Adjustments and (b) to an increase in the number of authorized shares of Common Stock to 350,000,000 shares of Common Stock under the Company’s Certificate of Incorporation, as amended.

Duration and Exercise Price

Each May 2025 Warrant offered hereby will have an exercise price of $[*] per share (110% of the combined public offering price per share of Common Stock and accompanying May 2025 Warrant). The